The ongoing, phase 2 ELAINE studies in women with advanced or metastatic ER+/HER2− breast cancer expressing ERα mutants are expected to provide further clinical data regarding the efficacy and safety of LAS as an antitumor therapy. The gene discussed is ESR1; the disease is breast cancer.